Clinical trial · Observational
The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])
A Matched Cohort Study of Regranex (Becaplermin) and the Risk of Cancer
NCT00518102CI-TRIAL-00023127completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare the risk of cancers in patients who have used REGRANEX (becaplermin) to that of patients with similar characteristics and health issues who have not used REGRANEX (becaplermin). REGRANEX (becaplermin) is topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diabetes Mellitus | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| REGRANEX (becaplermin) | Drug | — | UNRESOLVED |
| REGRANEX (becaplermin) comparators | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- 001
- description
- REGRANEX (becaplermin) A cohort of REGRANEX (becaplermin) users (ie patients treated with REGRANEX (becaplermin) a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
- interventionNames
- Drug: REGRANEX (becaplermin)
- label
- 002
- description
- REGRANEX (becaplermin) comparators A cohort of REGRANEX (becaplermin) nonusers (ie patients who are not treated with REGRANEX \[becaplermin\]) but are similar in characteristics to patients in the REGRANEX \[becaplermin\] user cohort)
- interventionNames
- Other: REGRANEX (becaplermin) comparators
Primary outcomes (1)
- measure
- The number of reported cases of cancers of all kinds, grouped by organ site in patients who have used REGRANEX (becaplermin) and patients who have not used not used REGRANEX (becaplermin).
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Must have at least 6 months of continuous enrollment in health plan prior to Regranex initiation Exclusion Criteria: * Any cancer-related diagnoses identified in the claims data during baseline (the 6 month period prior to REGRANEX (becaplermin) initiation).
References
Publications (0)
Data not yet available
No reference posted for this study.